# A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

> **NCT06884891** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 520 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** QL2108 injection
- **DRUG:** Dupixent®

## Key facts

- **NCT ID:** NCT06884891
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2027-05
- **Final completion:** 2028-04
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06884891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06884891, "A Phase Ⅲ Comparative Study of QL2108 to Dupixent®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06884891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*